The relationship between nonalcoholic fatty liver disease and the severity of coronary artery disease in patients with metabolic syndrome

Turk Kardiyoloji Dernegi Arsivi

Volumn 37, Issue 5, 2009, Pages 364-

  Uzun, Mehmet ^a   Yiǧiner, Ömer ^a   Kirilmaz, Ata ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ATORVASTATIN; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

ADULT; BLOOD; CASE REPORT; CORONARY ARTERY DISEASE; DRUG CONTRAINDICATION; FATTY LIVER; HUMAN; MALE; METABOLIC SYNDROME X; NOTE;

ADULT; ALANINE TRANSAMINASE; CORONARY ARTERY DISEASE; FATTY LIVER; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; METABOLIC SYNDROME X; PYRROLES;

EID: 77955477427     PISSN: 10165169     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Alper AT, Hasdemir H, Şahin S, Öntürk E, Akyol A, Nurkalem Z, et al. The relationship between nonalcoholic fatty liver disease and the severity of coronary artery disease in patients with metabolic syndrome. Türk Kardiyol Dern Arş 2008;36:376-81.
2. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356-62.
3. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA 2001;285:2486-97.
4. Hyogo H, Tazuma S, Arihiro K, Iwamoto K, Nabeshima Y, Inoue M, et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 2008;57:1711-8.
5. Siebler J, Galle PR. Treatment of nonalcoholic fatty liver disease. World J Gastroenterol 2006;12:2161-7.